CVKD
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$1.22
−4.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 956.00 | — | — | — | 1.3K |
| Gross Profit | (956.00) | — | — | — | (1.3K) |
| Operating Expenses | |||||
| R&D Expense | 2.8M | 4.1M | 4.2M | 4.1M | 392.9K |
| SG&A Expense | 8.8M | 9.4M | 6.8M | 3.5M | 2.3M |
| General & Admin Expense | 8.8M | 9.4M | 6.8M | 3.5M | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 2.0K | 6.9K | 1.9K | 2.0K | — |
| Total Operating Expenses | 11.7M | 13.5M | 11.0M | 7.6M | 2.7M |
| Cost and Expenses | 11.7M | 13.5M | 11.0M | 7.6M | 2.7M |
| Operating Income (EBIT) | (11.7M) | (13.5M) | (11.0M) | (7.6M) | (2.7M) |
| Non-Operating | |||||
| Interest Income | 109.9K | 223.8K | 309.3K | 249.1K | — |
| Interest Expense | — | — | — | 17.1K | 107.1K |
| Net Interest Income | 109.9K | 223.8K | 309.3K | 232.0K | (107.1K) |
| Other Non-Op Income/Expense | 109.9K | 223.8K | 309.3K | (724.2K) | (4.0M) |
| Non-Operating Income (excl Interest) | (92.1K) | (223.8K) | (309.3K) | 707.1K | 3.9M |
| EBT (Pre-Tax Income) | (11.5M) | (13.2M) | (10.7M) | (8.4M) | (6.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (11.5M) | (13.2M) | (10.7M) | (8.4M) | (6.7M) |
| Earnings from Cont. Ops | (11.5M) | (13.2M) | (10.7M) | (8.4M) | (6.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.5M) | (13.2M) | (10.7M) | (8.4M) | (6.7M) |
| Per Share | |||||
| Basic EPS | ($4.90) | ($6.64) | ($8.73) | ($9.63) | ($8.66) |
| Diluted EPS | ($4.90) | ($6.64) | ($8.73) | ($9.63) | ($8.66) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 2.9M | 2.0M | 1.2M | 868183 | 775638 |
| Diluted Shares Outstanding | 2.9M | 2.0M | 1.2M | 868183 | 775638 |
| Profitability Metrics | |||||
| EBITDA | (11.6M) | (13.2M) | (10.6M) | (8.3M) | (6.6M) |
| D&A | 2.0K | 6.9K | 1.9K | 2.0K | 1.3K |
| EBIT | (11.6M) | (13.2M) | (10.7M) | (8.3M) | (6.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026